```
554 Supplementary Materials
```
Additional file 1 — Stan code for the Bayesian multivariate hierarchical model

```
556 1 data {
557 2 int <lower=0> N; // number of observations
558 3 int <lower=0> D; // number of of binary outcomes
559 4 int <lower=2> L; // number of WHO categories
560 5 int <lower=0> P_main; // number of pre - treatment
561 characteristics in the main effects term
562 6 int <lower=0> P_inter; // number of pre - treatment
563 characteristics in the interaction effects term
5647 int<lower=1,upper=L> y_ord[N]; // vector of ordinal outcomes
565 8 int <lower=0,upper=1> y_b[N,D]; // matrix of D binary outcomes (N x D
566 matrix )
567 9 int <lower=0,upper=1> A[N]; // treatment or control
56810 row_vector[P_main] x_main[N]; // pre - treatment characteristics in
569 the main effects term (N x P_main matrix )
57011 row_vector[P_inter] x_inter[N]; // pre - treatment characteristics in
571 the interaction effects term (N x P_inter matrix )
5722 }
57313
5744 parameters {
5755 ordered [L-1] tau; \frac{1}{2} // cut-points for cumulative odds
576 model
57716 vector <lower=0>[(P_inter + 1)] sigma_beta; // sd of outcome - specific
578 treatment main effect and interaction effect
57917 vector[D] beta_0; // outcome - specific intercepts for D
580 binary outcomes
5818 matrix [P_main, (D + 1)] beta_1; // covariates main effect for D
582 binary outcomes and 1 ordinal outcome (P_main x (D + 1) matrix)
58319 vector[(P_inter + 1)] beta_star; // pooled treatment main effect and
584 pooled interaction effect across all outcomes
58520
58621 // non - central parameterization
58<sup>72</sup>
58823 matrix [(P_inter + 1), (D + 1)] z_beta_int;
58924 }
59025
59126 transformed parameters {
5927 matrix [(P_{\texttt{inter}} + 1), (D + 1)] beta_int; // outcome-specific
593 treatment main effect and interaction effect ((P_{\text{inter}} + 1) \times (D +594 1) matrix )
59528 vector[D] yhat_b[N];
59629 real yhat_ord[N];
59730
59831 for (j in 1:(P_inter + 1))
59932 for (k in 1:(D + 1)){
6003 beta_int[j,k] = beta_star[j] + sigma_beta[j] * z_beta_int[j,k];
60<sub>B4</sub> }
60235
60336 for (i in 1:N){
```

```
60437 for (k in 1:D){
6058 yhat_b[i,k] = beta_0[k] + x_main[i] * beta_1[,k] + (
606 append_col(1, x_inter[i]) * beta_int[,k]) * A[i];
60739 }
60840 yhat_ord[i] = x_main[i] * beta_1[,D+1] + (append_col(1, x_inter[
609 i]) * beta_int[,D+1]) * A[i];
61041 }
61142 }
61243
61344
61445 model {
61546
61647 // priors
61748
61849 sigma_beta ~ exponential(1);
61950 beta_star ~ normal(0,2.5);
62051 to_vector(beta_1) \sim normal(0,2.5);
6252 to_vector(z_beta_int) \tilde{ } std_normal();
62253
6234 for (l \text{ in } 1:(L-1))62455 tau[l] ~ student_t(3,0,8);
62556 }
62657
62758 for (k in 1:D){
62859 beta_0[k] ~ student_t(3,0,8);
62960 }
63061
63162 // outcome model
63263
63364 for (i in 1:N){
63465 y_ord[i] ~ ordered_logistic(yhat_ord[I], tau);
63566 for (k in 1:D){
6367 y_b[i,k] \tilde{ } bernoulli_logit(yhat_b[i,k]);
63768 }
63869 }
63970 }
```
- 640 Additional file 2 Main analysis: comparing the performance of the Bayesian multivariate and univariate models
- 641 when the true ITR is determined by potential outcomes
- 642 To implement this potential outcomes-based ITR, we first consider the patient characteristics \tilde{x}_i along with the true
- 643 values of parameters from the data generation process. Next, we use the *simstudy* package [\[43\]](#page--1-1) to generate
- ϵ 44 potential primary ordinal outcomes for subjects receiving the control treatment $(y_{A=0}^{(1)})$ and the experimental
- 645 treatment $(y_{A=1}^{(1)})$. The optimal ITR is derived from the indicator function $I(y_{A=1}^{(1)} < y_{A=0}^{(1)})$, which evaluates
- 646 whether the experimental treatment outcome is better than the control treatment outcome.
- 647 Utilizing this new potential outcomes-based ITR, the subsequent plot (Figure [A1\)](#page--1-2) illustrates the comparison of PCD and AUC values between the Bayesian multivariate and univariate models across varying training set sizes. In

Figure A1 Utilizing the new potential outcomes-based ITR: the boxplots of PCD and AUC in the test sets, comparing the multivariate (orange) and the univariate (blue) models across different training set sizes (as indicated in the x-axis).

648

649 comparison to Figure [1,](#page--1-3) the improvement in prediction using the multivariate model is less remarkable. This can be 650 attributed to the fact that generating potential outcomes based on probability inherently involves more randomness.

651 The gain in estimation is relatively small compared to the magnitude of this randomness. Consequently, when

652 considering prediction error, the improvement becomes less noticeable as it is overshadowed by the noise introduced

653 by the randomness.

654 Additional file 3 — Sensitivity analysis: comparing the performance of the Bayesian multivariate and univariate

655 models when the true ITR is determined by potential outcomes

656 Compared to Figure [2,](#page-0-1) the utilization of this new potential outcomes-based ITR yields less remarkable improvement

657 in the multivariate model's performance. This could be due to the probabilistic nature of generating potential

- 658 outcomes, which inherently involves more randomness. Despite the gain in estimation, the magnitude of this
- 659 randomness is relatively large, resulting in a small improvement that is overshadowed by the introduced noise when
- 660 considering prediction error.

661 Additional file 4 — The WHO 11-point COVID-19 clinical status scale.

- 0: Uninfected, no viral RNA detected
- 1: Asymptomatic, viral RNA detected
- 2: Symptomatic, independent
- 3: Symptomatic, assistance needed
- 4: Hospitalized, no oxygen therapy
- 5: Hospitalized, oxygen by mask or nasal prongs
- 6: Hospitalized, oxygen by non-invasive ventilation or high flow
- 7: Intubation & mechanical ventilation, $pO_2/FiO_2 \ge 150$ (or $SpO_2/FiO_2 \ge 200)^a$
- 8: Mechanical ventilation, pO2/FiO² *<* 150 (or SpO2/FiO² *<* 200) or vasopressors
- 9: Mechanical ventilation, pO2/FiO² *<* 150 and vasopressors, dialysis, or ECMO*^b*

10: Dead

*^a*pO2: partial pressure of oxygen, FiO2: fraction of inspired oxygen, SpO2: oxygen saturation. *^b*ECMO: extracorporeal membrane oxygenation.

Table A1 The WHO 11-point COVID-19 scale definition[\[39\]](#page-0-2).

	Control $(n = 1097)$	CCP ($n = 1190$)
$WHO = 0$	114	150
$WHO = 1$	151	168
$WHO = 2$	365	386
$WHO = 3$	134	142
$WHO = 4$	45	45
$WHO = 5$	86	84
$WHO = 6$	29	52
$WHO = 7$	23	30
$WHO = 8$	23	36
$WHO = 9$	33	22
$WHO = 10$	94	75

Table A2 The number of patients at different clinical stages of COVID-19 measured on the WHO 11-point scale at day 14 by treatment group.

- 662 Additional file 5 Goodness-of-fit using posterior predictive checking
- 663 In evaluating the suitability of a statistical model, it is crucial to determine whether the model provides an accurate
- 664 representation of the observed data. This is particularly important for models like the *co* model, which is built upon
- 665 a strong assumption of proportional cumulative odds. Posterior predictive checking serves as an effective way of
- 666 assessing a model's *goodness-of-fit* [\[47,](#page-0-3) [48\]](#page-0-4). This method operates on the premise that a well-fitted model should
- 667 enable the generation of replicated data (D^{rep}) that resembles the observed data (D^{original}) [\[49\]](#page-0-5).
- 668 The lack of fit can be measured by the Bayesian p-value, which represents the probability of the test statistic (e.g.,
- $P(Y \le y), y = 0, \ldots, 9$ for D^{rep} being equal to or exceeding the test statistic for D^{original} . A Bayesian p-value
- 670 approaching zero or one signifies a potential issue with the model's fit, whereas a value near 0.5 suggests that the
- 671 model captures the data well [\[42,](#page-0-6) [57\]](#page-0-7). We employed the procedure outlined in [\[41\]](#page-0-8) to examine the *co* model's fit to 672 the observed data and to compute the Bayesian p-value.
-
- 673 Table [A3](#page-0-9) provides the results of posterior predictive checking based on ten test statistics (along with their 95% CrIs)
- 674 for both the multivariate model (6) and univariate model (7) . Our analysis confirmed the satisfactory fit of both 675 models to the data.
	- Treatment Control CCP Test quantity: % subjects *T*(*D*original) 95% int. for *T*(*D*rep) Bayesian P value *T*(*D*original) 95% int. for *T*(*D*rep) Bayesian P value Multivariate model WHO \leq 0 10.39 [8.39, 12.94] 0.55 12.61 [10.08, 14.71] 0.39 WHO ≤ 1 24.16 [20.51, 26.80] 0.34 26.72 [23.28, 29.58] 0.41 WHO ≤ 2 57.43 [52.42, 59.43] 0.19 59.16 [55.71, 62.52] 0.48 WHO \leq 3 69.64 [65.36, 71.93] 0.29 71.09 [68.24, 74.45] 0.55 WHO ≤ 4 73.75 [69.92, 76.12] 0.32 74.87 [72.44, 78.32] 0.63 WHO \leq 5 81.59 [78.21, 83.68] 0.34 81.93 [80.17, 85.29] 0.74 WHO ≤ 6 84.23 [82.22, 87.15] 0.64 86.30 [83.78, 88.40] 0.44 WHO ≤ 7 86.33 [84.78, 89.43] 0.74 88.82 [86.13, 90.50] 0.33 WHO ≤ 8 88.42 [87.69, 91.89] 0.90 91.85 [88.82, 92.69] 0.14 $\text{WHO} \leq 9$ 91.43 [90.43, 94.07] 0.81 93.70 [91.26, 94.71] 0.22 Univariate model WHO ≤ 0 10.39 [8.57, 13.13] 0.62 12.61 [9.83, 14.54] 0.32 WHO ≤ 1 24.16 [20.78, 27.07] 0.41 26.72 [23.03, 29.41] 0.36 WHO \leq 2 57.43 [52.42, 59.80] 0.23 59.16 [55.55, 62.44] 0.46 WHO \leq 3 69.64 [65.45, 72.20] 0.31 71.09 [68.15, 74.45] 0.55 WHO ≤ 4 73.75 [69.83, 76.30] 0.34 74.87 [72.44, 78.40] 0.62 WHO \leq 5 81.59 [78.12, 83.87] 0.35 81.93 [80.17, 85.29] 0.74 WHO ≤ 6 84.23 [82.04, 87.24] 0.64 86.30 [83.78, 88.49] 0.45 WHO ≤ 7 86.33 [84.69, 89.52] 0.74 88.82 [86.13, 90.50] 0.34 $\text{WHO} \leq 8$ 88.42 [87.60, 91.89] 0.89 91.85 [88.82, 92.69] 0.14 $\text{WHO} \leq 9$ 91.43 [90.34, 94.17] 0.81 93.70 [91.34, 94.79] 0.23

Table A3 Summary of posterior predictive checking based on the ten test statistics.